Phase
Condition
Vascular Diseases
Proteinuria
Stress
Treatment
N/AClinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male or female over the age of 18 years
Diastolic blood pressure (DBP) greater tha 80 mmHg and less than 104 mmHg
Type II diabetes on diet or oral hypoglycemic agents with a hemoglobin A1C (HbA1C)less than 0.080
UA ratio albumin:creatinine 2.0 to 25 mg/mmol
Exclusion
Exclusion Criteria:
DBP > 104 mmhg
Woman not surgically sterile or menopausal.
Premenopausal women whoo are not surgically sterile or who are not practicingacceptable means of birth control and do not agree to submit to periodic pregnancytests.
Known or secondary forms of hypertension.
Intolerance to angiotensin (AT) 1 receptor blockers or angiotensin-converting enzyme (ACE) inhibitors.
Hepatic or renal dysfunction. Creatinine > 150 umol or enzymes greater than 2 timesupper limit of normal.
Hemodynamically significant renal artery stenosis, renal artery stenosis on a solitarykidney, post-renal transplant or with only one kidney.
Uncorrected volume depletion.
Biliary obstructive disorders.
NYHA functional class congestive heart failure (CHF) III-IV.
Coronary heart disease needing pharmacological therapy.
Stroke within the preceding six months.
Percutaneous transluminal coronary angioplasty (PTCA) within the preceding threemonths.
History of angioedema.
Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevantcardiac arrhythmias as determined by the clinical investigator.
Second or third degree AV block, left bundle branch block or any clinically relevantconduction abnormality as determined by the clinical investigator.
Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevantstenosis of aortic or mitral valve.
Administration of digoxin.
Patients with a fasting glucose greater than 7.0
History of drug or alcohol dependency.
Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin IIantagonists, alpha-blockers, beta-blockers, calcium channel antagonists, directvasodilators that cannot be stopped for the trial.
Administration of other non-antihypertensive medications known to affect bloodpressure (e.g. oral corticosteroids, monoamine oxidase [MAO] inhibitors, nitrates) atany time during the trial.
Chronic use of salt substitutes containing potassium chloride; potassium supplements;extreme dietary restrictions.
Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.
Clinically significant hyperkalemia as defined by serum potassium level greater than 5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level lessthan 3.0 mEq/L.
Patients receiving any investigational therapy within one month of signing theinformed consent form.
Known hypersensitivity to any component of telmisartan, ramipril orhydrochlorothiazide.
Any other clinical condition which, in the opinion of the principal investigator,would not allow safe completion of the protocol and safe administration of trialmedication.
Blood donation in the preceding 1 month.
Study Design
Study Description
Connect with a study center
Institut de Recherches Cliniques de Montreal
Montreal, Quebec J4X 1J3
CanadaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.